When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
KDMN - Mid-stage study underway for Kadmon's KD025 in systemic sclerosis
Kadmon Holdings Inc.
The first patient has been dosed in a Phase 2 clinical trial evaluating Kadmon Holdings' (NYSE:KDMN) lead candidate KD025 in patients with diffuse cutaneous systemic sclerosis (SSc), an inherited immune disorder characterized by fibrosis (scarring) of the skin and internal organs.
More news on: Kadmon Holdings, Inc., Healthcare stocks news,